Acute myeloid leukemia with t(8;16)(p11;p13) translocation

Acute myeloid leukemia (AML) with t(8;16)(p11;p13) translocation is a very rare subtype of blood cancer. In this disease, parts of chromosome 8 and chromosome 16 swap places, creating an abnormal fusion between two genes called KAT6A (also known as MYST3 or MOZ) and CREBBP (also known as CBP). This genetic change causes blood-forming cells in the bone marrow to grow out of control, producing large numbers of abnormal white blood cells that crowd out healthy blood cells. This subtype has some distinctive features that set it apart from other forms of AML. It is often associated with a specific type of white blood cell involvement called monocytic or myelomonocytic differentiation. A notable and unusual feature is that it can sometimes present with disseminated intravascular coagulation (DIC), a serious bleeding and clotting disorder. Another striking characteristic is that in newborns, this leukemia can occasionally go away on its own (spontaneous remission), though it may come back later. Symptoms are similar to other forms of AML and include fatigue, frequent infections, easy bruising or bleeding, fever, and bone pain. Treatment typically involves intensive chemotherapy, and in some cases, a bone marrow (stem cell) transplant may be recommended. The overall prognosis for this subtype is generally considered intermediate to poor, though outcomes vary depending on the patient's age, overall health, and response to initial treatment. Because of its rarity, treatment decisions are often guided by experience with AML in general, along with the specific clinical features of each patient's case.

Bring these to your next appointment

• Q1.What does the t(8;16) translocation mean for my specific treatment plan and prognosis?,Am I a candidate for a stem cell (bone marrow) transplant, and when would that be considered?,Are there any clinical trials available for this specific subtype of AML?,What are the signs of relapse I should watch for after treatment?,How will you manage the risk of disseminated intravascular coagulation (DIC)?,What supportive care will be provided during chemotherapy to manage side effects?,For neonatal cases: How often should blood work be monitored during spontaneous remission, and what would trigger starting treatment?

Common questions about Acute myeloid leukemia with t(8;16)(p11;p13) translocation